ProQR Therapeutics N.V. (Nasdaq: PRQR) (ProQR), a clinical-stage company dedicated to changing lives through transformative RNA therapies based on its proprietary Axiomer™ RNA editing technology ...

Netherlands-based ProQR is developing its experimental therapy, QR-421a, as a treatment for Usher syndrome. The rare disorder is caused by mutations to genes that provide the instructions for proteins ...

An RNA therapy from ProQR Therapeutics has failed a pivotal test in an inherited eye disorder, an unexpected setback to the biotech company’s most advanced program. According to the preliminary ...

ProQR Therapeutics has found a buyer for its ophthalmology assets. One year after putting the programs up for sale, the Dutch biotech has offloaded sepofarsen and ultevursen to Laboratoires Théa for ...

We are pleased to nominate Lykke to our Board of Directors,” said James Shannon, MD, Chairperson of the Board of ProQR Therapeutics. “Her extensive experience in global drug development and broad ...

ProQR focuses on RNA cell-editing therapies to treat rare diseases. The company lost roughly $117 million in cash in 2022. The company has eight therapies in its pipeline, but hasn't started clinical ...

In a reversal of fortunes, ProQR Therapeutics’ ophthalmology asset sale to Laboratoires Théa has been canceled after ProQR failed to meet the conditions of the deal. In August, Dutch biotech ProQR ...

Eli Lilly wants access to ProQR's RNA editing technology because it could be a more easily marketable alternative to gene therapy. Eli Lilly agreed to pay ProQR up to $1.3 billion to develop RNA ...

Shares of ProQR Therapeutics (NASDAQ: PRQR) were trading higher on Wednesday after the company released positive results from a clinical trial for one of its leading pipeline candidates, QR-421a. The ...

Shares of ProQR Therapeutics N.V. (NASDAQ: PRQR) were up 16% as of 3:48 p.m. EDT on Monday. ProQR didn't report any new announcements, but the biotech's update last Wednesday from a phase 1/2 clinical ...

ProQR scientists report for the first time in the ADAR RNA editing field in vivo proof of target engagement (RNA editing) leading to meaningful changes in biomarkers in NHPs using Axiomer™ RNA Editing ...

One stock that might be an intriguing choice for investors right now is ProQR Therapeutics N.V. PRQR. This is because this security in the Medical - Biomedical and Genetics space is seeing solid ...